Meeder Asset Management Inc. Trims Position in Regeneron Pharmaceuticals, Inc. $REGN

Meeder Asset Management Inc. decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 4,530 shares of the biopharmaceutical company’s stock after selling 1,106 shares during the quarter. Meeder Asset Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $2,547,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Marino Stram & Associates LLC boosted its holdings in Regeneron Pharmaceuticals by 5.3% in the 2nd quarter. Marino Stram & Associates LLC now owns 396 shares of the biopharmaceutical company’s stock valued at $208,000 after purchasing an additional 20 shares during the last quarter. CoreCap Advisors LLC increased its holdings in shares of Regeneron Pharmaceuticals by 9.2% during the 3rd quarter. CoreCap Advisors LLC now owns 238 shares of the biopharmaceutical company’s stock worth $134,000 after buying an additional 20 shares during the last quarter. Strait & Sound Wealth Management LLC raised its position in shares of Regeneron Pharmaceuticals by 3.5% during the 3rd quarter. Strait & Sound Wealth Management LLC now owns 628 shares of the biopharmaceutical company’s stock valued at $353,000 after buying an additional 21 shares during the period. CX Institutional lifted its holdings in Regeneron Pharmaceuticals by 7.9% in the second quarter. CX Institutional now owns 302 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 22 shares during the last quarter. Finally, Independence Bank of Kentucky grew its position in Regeneron Pharmaceuticals by 7.7% in the third quarter. Independence Bank of Kentucky now owns 308 shares of the biopharmaceutical company’s stock worth $173,000 after acquiring an additional 22 shares during the period. 83.31% of the stock is currently owned by institutional investors and hedge funds.

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Multiple analyst upgrades and higher targets — Bank of America and other firms raised ratings/targets this week, shifting consensus toward Buy and boosting investor confidence. Bank of America upgrade
• Positive Sentiment: Zacks moved REGN to a Zacks Rank #1 (Strong Buy), highlighting expectations for continued earnings outperformance. Zacks upgrade
• Positive Sentiment: Truist and other brokers raised price targets (Truist to $820), and aggregated analyst coverage (21‑analyst notes) points to a more favorable fundamental outlook — a catalyst for momentum buyers. 21‑analyst roundup
• Neutral Sentiment: Unusual options activity has picked up around REGN, signaling elevated trader interest and potential for amplified short‑term moves; direction is ambiguous. Unusual options activity
• Neutral Sentiment: Comparative analyst pieces (REGN vs peers) provide valuation context but are not immediate catalysts. REGN vs ILMN analysis
• Negative Sentiment: Insider selling: director Bonnie L. Bassler sold 1,500 shares at roughly $800 — a small dollar amount relative to market cap but sometimes triggers investor concern and short‑term profit‑taking. Insider sale SEC filing

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Cantor Fitzgerald upped their price target on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Morgan Stanley boosted their price objective on shares of Regeneron Pharmaceuticals from $767.00 to $768.00 and gave the company an “equal weight” rating in a report on Friday, December 12th. Canaccord Genuity Group increased their target price on shares of Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the stock a “buy” rating in a research note on Thursday, December 4th. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. Finally, UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Four investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $791.05.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of the firm’s stock in a transaction on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the sale, the director directly owned 1,703 shares in the company, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Christine A. Poon sold 6,500 shares of the business’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the transaction, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 8,431 shares of company stock worth $5,733,521. 7.02% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $796.55 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.33. The company has a market cap of $83.72 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 2.16 and a beta of 0.39. The stock’s 50-day moving average is $738.12 and its two-hundred day moving average is $629.56. Regeneron Pharmaceuticals, Inc. has a 1-year low of $476.49 and a 1-year high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion during the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the company posted $12.46 earnings per share. Analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Shareholders of record on Thursday, November 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.